BRIEF-MeiraGTx Holdings Says Primary Study Objective Of Safety And Tolerability Was Met
Oct 15 (Reuters) - MeiraGTx Holdings PLC :
* MEIRAGTX HOLDINGS: POSITIVE DATA FROM RANDOMIZED, SHAM-CONTROLLED CLINICAL BRIDGING STUDY OF AAV-GAD FOR TREATMENT OF PARKINSON'S DISEASE
* MEIRAGTX HOLDINGS PLC: PRIMARY STUDY OBJECTIVE OF SAFETY AND TOLERABILITY WAS MET
* MEIRAGTX HOLDINGS: SIGNIFICANT & CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE DEMONSTRATED FOR KEY EFFICACY ENDPOINTS AT 26 WEEKS
* MEIRAGTX HOLDINGS: AAV-GAD WAS SAFE & WELL TOLERATED, WITH NO SERIOUS ADVERSE EVENTS RELATED TO AAV-GAD TREATMENT
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available